The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.

With the expansion of Immuno-Oncology (I/O) drug development, effective preclinical I/O platforms are required for testing efficacy and safety of new I/O targets. Finally, a diversity of clinically predictive in vivo models are needed to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations before entering the clinic.

Speakers

	James Cooke Ph.D. Associate Director, Discovery, Core Phage, Bicycle Therapeutics Talk Title: TBA
	Kinmei Leung Ph.D. Director, Translational Sciences, F-Star Therapeutics Talk Title: TBA
	Joana Neves Scientist, Artios Pharma Ltd. Talk Title: TBA
	Roberto Solari Ph.D.  CEO, MYRICX Pharma Ltd Talk Title: Validation of N-Myristolytransferase (NMT) as a novel and selective oncology target.
	Yinfei Yin Ph.D. Executive Director, Head of Scientific Operations, UK & US Talk Title: TBA
	Jelena Urosevic Ph.D. Associate Principal Scientist, AstraZeneca Talk Title: TBA
	Barbara Cipriani Ph.D. Head of Biology, Pathios Therapeutics  Talk Title: Inhibitors of the pH sensing GPCR GPR65 counteract the immune suppressive effects driven by acidosis in macrophages and suppress tumour growth in syngeneic models.